Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Results from a European collaborative study

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1336-1342

  Gabay, Cem ^a   Riek, Myriam ^b   Hetland, Merete Lund ^c,d   Hauge, Ellen Margrethe ^e   Pavelka, Karel ^f   Tomšič, Matija ^g   Canhao, Helena ^h,i   Chatzidionysiou, Katerina ^j   Lukina, Galina ^k   Nordström, Dan C ^l   Lie, Elisabeth ^m   Ancuta, Ioan ⁿ   Hernández, M Victoria ^o   Van Riel, Piet L M C ^p   Van Vollenhoven, Ronald ^j   Kvien, Tore K ^m  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b SCQM Foundation   (Switzerland)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^h INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

ⁱ Rheumatic Diseases Portuguese Register (Reumapt)   (Portugal)

^j KAROLINSKA INSTITUTE   (Sweden)

^k V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m DIAKONHJEMMET HOSPITAL   (Norway)

ⁿ CANTACUZINO INSTITUTE   (Romania)

^o HOSPITAL CLÍNIC   (Spain)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RHEUMATOID FACTOR; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CZECH REPUBLIC; DENMARK; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG RESPONSE; DRUG RETENTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINLAND; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; NORWAY; OBSERVATIONAL STUDY; PORTUGAL; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RUSSIAN FEDERATION; SLOVENIA; SWEDEN; SWITZERLAND; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; EUROPE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84941695386     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207760     Document Type: Article

References (19)

1. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371: 987-97.
2. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
3. Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 2013;40:113-26.
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73: 492-509.
5. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
6. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
7. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
8. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
9. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73:803-9.
10. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2015;74:35-43.
11. Takeuchi T, Kaneko Y, Atsumi T, et al. Adding Tocilizumab or switching to Tocilizumab monotherapy in RA patients with inadequate response to Methotrexate: 24-week results from a randomized controled study (surprise study). Ann Rheum Dis 2013;72(Suppl 3):62.
12. Gabay C, Riek M, Scherer A, et al. Effectiveness of biological DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis -data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) Published Online First: 27 Apr 2015.
13. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
14. Takeuchi T, Kaneko Y, Atsumi T, et al. Clinical and radiographic effects after 52-week of adding Tocilizumab or switching to tocilizumab in RA patients with inadequate response to methotrexate: results from a prospective randomized controlled study (SURPRISE study). Ann Rheum Dis 2014;73(Suppl 2):686.
15. Bykerk V, Östör AJK, Alvaro-Gracia J, et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol 2015;34:563-71.
16. Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford) 2015;54:113-20.
17. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 2010;29:2920-31.
18. Allison PD. Multiple imputation for missing data: a cautionary tale. Sociol Method Res 2000;28:301-9.
19. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd edn, Oxford: Wiley, 2002.